Payment overview · 2025
General Payments
$453.54
22 reported records · 12 companies
Healthcare provider profile · identity verified
Mubushar Ikram Raza
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · BRENTWOOD, NY · NPI 1588017164
Verified facts
What the public records show
CMS Open Payments records show Mubushar Ikram Raza received $453.54 in general payments during 2025 across 22 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Movantik, Relistor, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Zubsolv by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Relistor by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.96 | 20.3% | 5 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $78.96 | 17.4% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $57.18 | 12.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.30 | 10.2% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $42.90 | 9.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.07 | 5.1% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $22.93 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.71 | 4.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.63 | 4.1% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $18.19 | 4.0% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $17.32 | 3.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.39 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $453.54 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.96 | 5 | 2025 |
Source payment records
|
|||||
| Prialt Normalized: prialt |
Drug | TerSera Therapeutics LLC | $78.96 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $57.18 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.30 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.30 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOVANTIK movantik |
2025 | Movantik | 2024 | 36 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 30 | exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1030 | 184 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 709 | 140 |
| Lidocaine | Lidocaine | 466 | 82 |
| Gabapentin | Gabapentin | 461 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 306 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 285 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 257 | 60 |
| Tramadol Hcl | Tramadol Hcl | 186 | 41 |
| Morphine Sulfate Er | Morphine Sulfate | 185 | 30 |
| Oxycontin | Oxycodone Hcl | 162 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 152 | 47 |
| Methadone Hcl | Methadone Hcl | 131 | 23 |
| Pregabalin | Pregabalin | 129 | 30 |
| Mounjaro | Tirzepatide | 118 | 29 |
| Carisoprodol | Carisoprodol | 115 | 20 |
| Ibuprofen | Ibuprofen | 111 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 21 |
| Diazepam | Diazepam | 99 | 22 |
| Morphine Sulfate | Morphine Sulfate | 84 | 22 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 79 | 13 |
| Meloxicam | Meloxicam | 79 | 24 |
| Baclofen | Baclofen | 70 | 16 |
| Trazodone Hcl | Trazodone Hcl | 69 | 16 |
| Ozempic | Semaglutide | 55 | 15 |
| Fentanyl | Fentanyl | 54 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 51 | suppressed |
| Alprazolam | Alprazolam | 47 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Xtampza Er | Oxycodone Myristate | 41 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 16 |
| Movantik | Naloxegol Oxalate | 36 | 13 |
| Topiramate | Topiramate | 35 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 34 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 14 |
| Quviviq | Daridorexant Hcl | 32 | suppressed |
| Relistor | Methylnaltrexone Bromide | 30 | 14 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 24 | suppressed |
| Metformin Hcl | Metformin Hcl | 24 | 11 |
| Naproxen | Naproxen | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | 13 |
| Omeprazole | Omeprazole | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 19 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.54 · 22 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | CONTRAVE, GLYCATE, JOURNAVX, MOVANTIK, NURTEC ODT, Prialt, QULIPTA, RELISTOR, RELTONE 200 MG, RELTONE 400 MG, UBRELVY, XTAMPZA, ZAVZPRET, ZTLido, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Movantik play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error